No evidence for WT1 involvement in a beta-catenin-independent activation of the Wnt signaling pathway in pituitary adenomas

Endocrine Pathology

Volumn 20, Issue 3, 2009, Pages 158-162

  Schittenhelm, J ^a   Psaras, T ^a   Honegger, J ^a   Trautmann, K ^a   Meyermann, R ^a   Beschorner, R ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Adenohypophysis; Oncogene; Pituitary adenoma; WT1

Indexed keywords

BETA CATENIN; GONADOTROPIN; WNT PROTEIN; WT1 PROTEIN; TRANSCRIPTION FACTOR PIT 1;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOPLASM; ENDOTHELIUM CELL; ENZYME ACTIVATION; EPITHELIUM CELL; FEMALE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; HYPOPHYSIS; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MESENCHYME; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ADENOMA; BIOSYNTHESIS; HYPOPHYSIS TUMOR; METABOLISM; MIDDLE AGED; PHYSIOLOGY; TISSUE MICROARRAY;

ADENOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTOR PIT-1; WT1 PROTEINS; YOUNG ADULT;

EID: 70449698773     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12022-009-9078-y     Document Type: Article

References (31)

1. Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia 21:868-876, 2007. (Pubitemid 46672061)
2. Buckler AJ, Pelletier J, Haber DA, Glaser T, Housman DE. Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development. Mol Cell Biol 11:1707-1712, 1991. (Pubitemid 21895530)
3. Hastie ND. The genetics of Wilms' tumor-a case of disrupted development. Annu Rev Genet 28:523-558, 1994.
4. Wang ZY, Qiu QQ, Huang J, Gurrieri M, Deuel TF. Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways. Oncogene 10:415-422, 1995.
5. Maheswaran S, Park S, Bernard A, Morris JF, Rauscher FJ 3rd, Hill DE, et al. Physical and functional interaction between WT1 and p53 proteins. Proc Natl Acad Sci USA 90:5100-5104, 1993. doi:10.1073/pnas.90.11.5100 (Pubitemid 23182984)
6. Ueda T, Oji Y, Naka N, Nakano Y, Takahashi E, Koga S, et al. Overexpression of the Wilms' tumor gene WT1 in human bone and soft-tissue sarcomas. Cancer Sci 94:271-276, 2003. doi:10.1111/j.1349-7006.2003.tb01432.x (Pubitemid 36575894)
7. Menssen HD, Bertelmann E, Bartelt S, Schmidt RA, Pecher G, et al. Wilms' tumor gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor specimens. J Cancer Res Clin Oncol 126:226-232, 2000. doi:10.1007/s004320050037 (Pubitemid 30183026)
8. Loeb DM, Evron E, Patel CB, Sharma PM, Niranjan B, Buluwela L, et al. Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res 61:921-925, 2001. (Pubitemid 32174404)
9. Rodeck U, Bossler A,Kari C,Humphreys CW, Györfi T,Maurer J, et al. Expression of the wt1 Wilms' tumor gene by normal and malignant human melanocytes. Int J Cancer 59:78-82, 1994. doi:10.1002/ijc.2910590116 (Pubitemid 24310952)
10. Timár J, Mészáros L, Orosz Z, Albini A, Rásó E. WT1 expression in angiogenic tumours of the skin. Histopathology 47:67-73, 2005. doi:10.1111/j.1365-2559.2005.02169.x (Pubitemid 40978815)
11. Oji Y, Suzuki T, Nakano Y, Maruno M, Nakatsuka S, Jomgeow T, et al. Overexpression of the Wilms' tumor gene W T1 in primary astrocytic tumors. Cancer Sci 95:822-827, 2004. doi:10.1111/j.1349- 7006.2004.tb02188.x (Pubitemid 39545589)
12. Schittenhelm J, Beschorner R, Simon P, Tabatabai G, Herrmann C, Schlaszus H, et al. Diagnostic value of WT1 in neuroepithelial tumours. Neuropathol Appl Neurobiol 35:69-81, 2009. doi:10.1111/ j.1365-2990.2008.00957.x
13. Central Brain Tumor Registry of the United States. http://www. cbtrus.org/reports/reports.html. Accessed on 1 March 2009.
14. Asa SL, Ezzat S. The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 19:798-827, 1998. doi:10.1210/er.19.6.798 (Pubitemid 128506522)
15. Honegger J, Zimmermann S, Psaras T, Petrick M, Mittelbronn M, Ernemann U, et al. Growth modelling of non-functioning pituitary adenomas in patients referred for surgery. Eur J Endocrinol 158:287-294, 2008. doi:10.1530/EJE-07- 0502 (Pubitemid 351404991)
16. Heaney AP, Melmed S. New pituitary oncogenes. Endocr Relat Cancer 7:3-15, 2000. doi:10.1677/erc.0.0070003 (Pubitemid 30305867)
17. Miyakoshi T, Takei M, Kajiya H, Egashira N, Takekoshi S, Teramoto A, et al. Expression of Wnt4 in human pituitary adenomas regulates activation of the beta-catenin-independent pathway. Endocr Pathol 19:261-273, 2008. doi:10.1007/s12022-008-9048-9
18. Sim EU, Smith A, Szilagi E, Rae F, Ioannou P, Lindsay MH, et al. Wnt-4 regulation by the Wilms' tumour suppressor gene, WT1. Oncogene 21:2948-2960, 2002. doi:10.1038/sj.onc.1205373 (Pubitemid 34522894)
19. DeLellis RA, Lloyd RV, Heitz PU, et al. Pathology and genetics, WHO classification of tumours of endocrine organs. Lyon: IARC; 2004.
20. Lawley LP, Cerimele F, Weiss SW, North P, Cohen C, Kozakewich HP, et al. Expression of Wilms tumor 1 gene distinguishes vascular malformations from proliferative endothelial lesions. Arch Dermatol 141:1297-1300, 2005. doi:10.1001/ archderm.141.10.1297 (Pubitemid 41498928)
21. Chang J, Sonoyama W, Wang Z, Jin Q, Zhang C, Krebsbach PH, et al. Noncanonical Wnt-4 signaling enhances bone regeneration of mesenchymal stem cells in craniofacial defects through activation of p38 MAPK. J Biol Chem 282:30938-30948, 2007. doi:10.1074/jbc.M702391200 (Pubitemid 350035235)
22. Tomizuka K, Horikoshi K, Kitada R, Sugawara Y, Iba Y, Kojima A, et al. R-spondin1 plays an essential role in ovarian development through positively regulating Wnt-4 signaling. Hum Mol Genet 17:1278-1291, 2008. doi:10.1093/hmg/ddn036 (Pubitemid 351566964)
23. Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 19:804-814, 2006. (Pubitemid 43780450)
24. Kumar-Singh S, Segers K, Rodeck U, Backhovens H, Bogers J, Weyler J, et al. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. J Pathol 181:67-74, 1997. doi:10.1002/(SICI)1096-9896(199701)181: 1<67::AIDPATH723>3.0.CO;2-Z (Pubitemid 27099776)
25. Graham K, Li W, Williams BR, Fraizer G. Vascular endothelial growth factor (VEGF) is suppressed in WT1-transfected LNCaP cells. Gene Expr 13:1-14, 2006. doi:10.3727/000000006783991953
26. Hanson J, Gorman J, Reese J, Fraizer G. Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor,WT1. Front Biosci 12: 2279-2290, 2007. doi:10.2741/2230
27. Saeger W, Bosse U, Pfingst E, Schierke G, Kulinna H, Atkins D, et al. Prolactin producing hypophyseal carcinoma. Case report of an extremely rare metastatic tumor. Pathologe 16:354-358, 1995. doi:10.1007/s002920050114
28. Heshmati HM, Scheithauer BW, Young WF. Metastases to the pituitary gland. Endocrinologist 12:45-49, 2002.
29. Saeger W, Riedel M, Schröder H. Metastasen in der Hypophyse und Sella. Pathologe 6:308-312, 1985.
30. Kourea HP, Adonakis G, Androutsopoulos G, Zyli P, Kourounis G, Decavalas G. Fallopian tube malignant mixed müllerian tumor (carcinosarcoma): a case report with immunohistochemical profiling. Eur J Gynaecol Oncol 29:538-542, 2008.
31. Zhao C, Barner R, Vinh TN, McManus K, Dabbs D, Vang R. SF- 1 is a diagnostically useful immunohistochemical marker and comparable to other sex cord-stromal tumor markers for the differential diagnosis of ovarian sertoli cell tumor. Int J Gynecol Pathol 27:507-514, 2008. doi:10.1097/PGP. 0b013e31817c1b0a